News Sentiment

ICCC sentiment intelligence

ImmuCell Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.89 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

75/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+5.8% over one week, +12.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Price to earnings forward of ImmuCell Corporation – NASDAQ:ICCC

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 75/100 classification
One-week reaction 5.8% Price confirming higher
Trend fit Trend active 12.5% over four weeks
Fair value 94.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 26
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 8
TradingKey 8
TradingView 4
dars.gov.et 4
simplywall.st 3
The Globe and Mail 3
Investing.com 2

Event Lens

What the news is about

Classified themes
Earnings 24
Market update 20
Macro sensitivity 3
Analyst action 2
Deals and strategy 1
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-52 of 52
Stock Titan Direct company coverage

Iccell plans $3.5M First Defense capacity boost | ICCC 8-K Filing

ImmuCell Corporation (NASDAQ: ICCC) has announced a significant manufacturing capacity expansion for its flagship First Defense® product line, shifting resources from its previously planned Re-Tain® production. The first phase, costing approximately $3.5 million and taking about

Tone
Positive 64/100
Event
Market update
Published
10 Jun 2026 19:39
Source
Stock Titan
Market source Direct company coverage

ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand

ImmuCell (ICCC) reported strong first-quarter 2026 results with product sales up 28.4% to $10.4 million and net income rising 34% to $1.9 million. The company's performance was driven by robust demand for its First Defense calf-scours prevention products, particularly Tri-Shield,

Tone
Positive 94/100
Event
Earnings
Published
25 May 2026 13:45
Source
Market source
The Globe and Mail Direct company coverage

ImmuCell Reaches Settlement Agreement with Norbrook Laboratories

ImmuCell Corporation has reached a settlement agreement with Norbrook Laboratories Limited concerning claims related to their 2019 Development Services and Commercial Supply Agreement. Norbrook will pay ImmuCell $2,000,000, and both parties deny admission of liability. TipRanks'

Tone
Neutral 50/100
Event
Macro sensitivity
Published
19 May 2026 07:44
Source
The Globe and Mail
Barchart.com Direct company coverage

ImmuCell Q1 Earnings Call Highlights

ImmuCell (NASDAQ:ICCC) reported a record first quarter for 2026, achieving over $10 million in product sales for the first time, a 28.4% increase from the previous year. The company's strategic focus on its First Defense calf scours prevention portfolio and improvements in manufa

Tone
Negative 41/100
Event
Earnings
Published
16 May 2026 14:39
Source
Barchart.com
Insider Monkey Direct company coverage

ImmuCell Corporation (NASDAQ:ICCC) Q1 2026 Earnings Call Transcript

ImmuCell Corporation reported a record-setting first quarter in 2026, achieving $10.4 million in revenue, a 28.4% increase year-over-year, and a 34% rise in net income. The company's strategic shift to focus on its "First Defense" calf scours preventative product has started yiel

Tone
Neutral 50/100
Event
Earnings
Published
16 May 2026 12:38
Source
Insider Monkey
Stock Titan Direct company coverage

ICCC SEC Filings - Immucell 10-K, 10-Q, 8-K Forms

This article provides an overview of Immucell (ICCC) SEC filings, including 10-K, 10-Q, and 8-K forms, which document material events and governance. It highlights recent filings such as the company replacing higher-rate loans with new financing and the initiation of a CEO succes

Tone
Neutral 50/100
Event
Market update
Published
16 May 2026 06:38
Source
Stock Titan
Stock Titan Direct company coverage

ImmuCell (NASDAQ: ICCC) grows Q1 2026 revenue 28% and boosts earnings

ImmuCell Corporation reported strong financial results for Q1 2026, with product sales increasing by 28.4% to $10.36 million and net income rising by 34.2% to $1.94 million. This growth was primarily driven by higher sales volumes and price increases for its First Defense® produc

Tone
Positive 75/100
Event
Earnings
Published
14 May 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

Calf-health maker ImmuCell secures $2M to expand First Defense output

ImmuCell (Nasdaq: ICCC) reported a significant increase in Q1 2026 net income to $1.9 million on product sales of $10.4 million, marking a 28.4% year-over-year growth. The company achieved a gross margin of 45.0% and increased its cash position to $6.8 million, bolstered by a $2

Tone
Positive 64/100
Event
Earnings
Published
14 May 2026 19:40
Source
Stock Titan